Trials / Completed
CompletedNCT02062645
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | amlodipine/valsartan | Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2014-02-14
- Last updated
- 2017-03-28
- Results posted
- 2017-03-28
Locations
8 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02062645. Inclusion in this directory is not an endorsement.